This optimized protocol resulted in highly efficient tumorigenesis in 2–3 weeks with 100% penetrance and 100% bilateral tumor onset for the KRAS/Trp53 model for both P30 and P0 EPO (Supplementary Fig. 1e–g). The gene discussed is KRAS; the disease is neoplasm.